

Consolidated Financial Statements

June 30, 2023 and 2022

(With Independent Auditors' Report Thereon)

# **Table of Contents**

	Page(s)
Independent Auditors' Report	1–2
Consolidated Financial Statements:	
Consolidated Balance Sheets	3–4
Consolidated Statements of Operations and Changes in Net Assets Without Donor Restrictions	5
Consolidated Statements of Changes in Net Assets	6
Consolidated Statements of Cash Flows	7
Notes to Consolidated Financial Statements	8–34



KPMG LLP Suite 3800 1300 South West Fifth Avenue Portland, OR 97201

#### Independent Auditors' Report

The Board of Directors PeaceHealth Networks:

#### Opinion

We have audited the consolidated financial statements of PeaceHealth Networks and its subsidiaries (the Corporation), which comprise the consolidated balance sheets as of June 30, 2023 and 2022, and the related consolidated statements of operations and changes in net assets without donor restrictions, changes in net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the Corporation as of June 30, 2023 and 2022, and the results of its operations and its cash flows for the years then ended in accordance with U.S. generally accepted accounting principles.

## Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the Corporation and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with U.S. generally accepted accounting principles, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Corporation's ability to continue as a going concern for one year after the date that the consolidated financial statements are issued.

# Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.



In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether
  due to fraud or error, and design and perform audit procedures responsive to those risks. Such
  procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the
  consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that
  are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
  effectiveness of the Corporation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that
  raise substantial doubt about the Corporation's ability to continue as a going concern for a reasonable
  period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

KPMG LLP

Portland, Oregon October 10, 2023

# **Consolidated Balance Sheets**

# June 30, 2023 and 2022

(In thousands)

Assets	_	2023	2022
Current assets: Cash and cash equivalents	\$	112,225	43,699
Short-term investments	*	731,791	701,862
Accounts receivable		396,871	380,665
Other receivables		74,797	66,777
Pending trades receivable		33,483	98,927
Inventory of supplies		91,744	112,012
Prepaid expenses and other		44,900	38,828
Assets whose use is limited that are required for current liabilities	_	41,277	14,096
Total current assets	_	1,527,088	1,456,866
Assets whose use is limited:			
Investments		1,457,598	1,619,835
Investments in joint ventures and other	_	83,452	81,453
Total assets whose use is limited		1,541,050	1,701,288
Less current portion	_	(41,277)	(14,096)
Net assets whose use is limited	_	1,499,773	1,687,192
Property, plant, and equipment:			
Land and improvements		159,899	150,928
Buildings, fixed equipment, and other		1,894,287	1,949,274
Moveable equipment		1,188,810	1,123,522
Construction in progress	_	214,698	118,253
Total property, plant, and equipment		3,457,694	3,341,977
Less accumulated depreciation	_	(2,138,514)	(2,121,432)
Net property, plant, and equipment		1,319,180	1,220,545
Interest in net assets of related foundations		145,520	131,994
Operating lease right-of-use assets		95,009	88,918
Other assets	_	101,549	105,548
Total assets	\$_	4,688,119	4,691,063

# **Consolidated Balance Sheets**

June 30, 2023 and 2022

(In thousands)

Liabilities and Net Assets	2023	2022
Current liabilities:		
Accounts payable \$	181,617	179,027
Accrued payroll, payroll taxes, and employee benefits	214,200	222,689
Accrued interest payable	5,984	5,594
Medicare advanced funding	_	89,419
Current portion of operating lease liabilities	11,834	10,425
Other current liabilities	63,936	58,513
Pending trades payable	35,667	25,621
Current portion of long-term debt	8,073	14,409
Total current liabilities	521,311	605,697
Other long-term liabilities	256,046	249,180
Long-term operating lease liabilities, net of current portion	87,781	82,817
Long-term debt, net of current portion	1,656,660	1,449,334
Net assets:		
Without donor restrictions, controlling interest	1,979,618	2,126,685
Without donor restrictions, noncontrolling interest	2,372	2,397
With donor restrictions	184,331	174,953
Total net assets	2,166,321	2,304,035
Total liabilities and net assets \$	4,688,119	4,691,063

# Consolidated Statements of Operations and Changes in Net Assets Without Donor Restrictions Years ended June 30, 2023 and 2022

(In thousands)

<u> </u>	2023	2022
Revenues: Patient service revenue \$	3,297,352	2 102 244
Patient service revenue \$ Other operating revenue	90,729	3,103,344 187,273
Total revenues	3,388,081	3,290,617
Expenses:		
Salaries and wages	1,841,411	1,876,501
Payroll taxes and benefits	353,556	308,098
Supplies	580,085	521,794
Purchased services	475,491	453,460
Other	216,214	217,259
Depreciation and amortization	138,976	148,969
Interest and amortization of deferred financing costs	51,831	42,146
Total expenses	3,657,564	3,568,227
Loss from recurring operations	(269,483)	(277,610)
Nonrecurring operating loss	(19,122)	(16,494)
Loss from operations	(288,605)	(294,104)
Other income (expense):		
Investment return, net	134,485	(260,119)
Net change in interest rate swaps	14,133	49,901
Other	(15,155)	(96,969)
Total other income (expense)	133,463	(307,187)
Deficit of revenues over expenses	(155,142)	(601,291)
Net assets released from restrictions for property, plant, and equipment	9,828	4,254
Change in pension liability	126	69,522
Other	(1,904)	(1,811)
Decrease in net assets without donor restrictions \$	(147,092)	(529,326)

#### Consolidated Statements of Changes in Net Assets

Years ended June 30, 2023 and 2022

(In thousands)

		Without do	nor restrictions			
	=	Controlling interest	Noncontrolling interest	With donor restrictions	Total	
Net assets at June 30, 2021	\$	2,651,418	6,990	103,332	2,761,740	
(Deficit) excess of revenues over expenses		(601,929)	638		(601,291)	
Restricted contributions		<del></del>	_	4,254	4,254	
Net assets released from restrictions		4,254	_	(5,095)	(841)	
Change in interest in net assets of related foundations		_	_	52,777	52,777	
Change in pension liability		69,522	_	_	69,522	
Other	_	3,420	(5,231)	19,685	17,874	
Change in net assets	_	(524,733)	(4,593)	71,621	(457,705)	
Net assets at June 30, 2022	_	2,126,685	2,397	174,953	2,304,035	
Deficit of revenues over expenses		(155,117)	(25)	_	(155,142)	
Restricted contributions		_	_	9,828	9,828	
Net assets released from restrictions		9,828	_	(9,828)	_	
Change in interest in net assets of related foundations		_	_	13,552	13,552	
Change in pension liability		126	_	· —	126	
Other	_	(1,904)		(4,174)	(6,078)	
Change in net assets	_	(147,067)	(25)	9,378	(137,714)	
Net assets at June 30, 2023	\$_	1,979,618	2,372	184,331	2,166,321	

# Consolidated Statements of Cash Flows

# Years ended June 30, 2023 and 2022

(In thousands)

	_	2023	2022
Cash flows from operating activities:			
Change in net assets	\$	(137,714)	(457,705)
Adjustments to reconcile change in net assets to net cash (used in) provided by operating activities:		, ,	, ,
Depreciation and amortization		138,976	148,969
Loss (gain) on sale of property, plant, and equipment		189	(303)
Change in pension liability		(126)	(69,522)
Restricted contributions		(9,828)	(4,254)
Net change in realized and unrealized (gains) losses on investments		(104,621)	302,498
Valuation adjustments on swap arrangements		(18,648)	(62,678)
Change in interest in net assets of related foundations		(13,552)	(52,777)
Equity earnings on investments, net of distributions		8,574	862
Gain on sale of joint venture		(2,590)	_
Changes in operating assets and liabilities:			
Decrease (increase) in:		(40.000)	(40 =0=)
Accounts receivable		(16,206)	(46,707)
Other assets		76,361	(129,323)
Increase (decrease) in:		0.500	24.005
Accounts payable		2,590	31,985
Medicare advanced funding		(89,419)	(63,815) 4,204
Accrued payroll, payroll taxes, and employee benefits Other liabilities		(8,489)	
Other liabilities	_	41,806	(77,233)
Net cash used in operating activities	_	(132,697)	(475,799)
Cash flows from investing activities:			
Purchase of property, plant, and equipment		(239,061)	(167,341)
Proceeds from sale of joint venture		7,300	_
Proceeds from sale of land held for sale and property, plant, and equipment		519	3,999
Purchase of alternative investments		(188,061)	(215,045)
Sales of alternative investments		210,432	130,641
Sales (purchases) of investments, net	_	199,276	564,994
Net cash (used in) provided by investing activities	_	(9,595)	317,248
Cash flows from financing activities:			
Principal payments on long-term debt		(14,010)	(11,040)
Proceeds from new financing		215,000	27,450
Proceeds from restricted contributions	_	9,828	4,254
Net cash provided by financing activities	_	210,818	20,664
Net increase (decrease) in cash and cash equivalents		68,526	(137,887)
Cash and cash equivalents at beginning of year	_	43,699	181,586
Cash and cash equivalents at end of year	\$ _	112,225	43,699
Supplemental disclosure of cash flow information: Capital expenditures included in accounts payable	\$	17,519	9,218

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

(In thousands)

# (1) Organization

# (a) Corporate Structure

PeaceHealth Networks is a Washington not-for-profit corporation, recognized as tax exempt pursuant to Section 501(c)(3) of the Internal Revenue Code, which is the sole corporate member of PeaceHealth, which is also a Washington not-for-profit corporation, recognized as tax exempt pursuant to Section 501(c)(3) of the Internal Revenue Code, with its corporate office located in Vancouver, Washington. PeaceHealth Networks is not affiliated with the Roman Catholic Church, currently has no operations, and currently holds no financial assets in its own name; however, it is the member corporation of PeaceHealth, which is a Private Pontifical Juridic Person according to the canon law of the Roman Catholic Church, and does have extensive healthcare operations and holds substantial financial assets. PeaceHealth Networks and its associated entities are collectively referred to herein as "the Corporation." PeaceHealth Networks and PeaceHealth are the only members of the Corporation's obligated group. At June 30, 2023, the following regional healthcare delivery systems and operating divisions are components of PeaceHealth:

# Northwest Network:

PeaceHealth Ketchikan Medical Center PeaceHealth St. Joseph Medical Center Peace Island Medical Center PeaceHealth United General Medical Center

#### Columbia Network:

PeaceHealth St. John Medical Center PeaceHealth Southwest Medical Center

## Oregon West Network:

PeaceHealth Sacred Heart Medical Center at University District PeaceHealth Sacred Heart Medical Center at RiverBend PeaceHealth Cottage Grove Community Medical Center PeaceHealth Peace Harbor Medical Center

# Systemwide Organizations:

## PeaceHealth Medical Group

These regional healthcare delivery systems and operating divisions provide inpatient, outpatient, primary, and specialty care and home care services in Alaska, Washington, and Oregon. These divisions primarily operate in Ketchikan, Alaska; Bellingham, Friday Harbor, Sedro Woolley, Longview, and Vancouver, Washington; and Springfield, Eugene, Florence, and Cottage Grove, Oregon.

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

(In thousands)

PeaceHealth Networks included the following controlled affiliates at June 30, 2023:

PeaceHealth
Health Ventures
Pooled Income Funds (including Charitable Life Income Funds)
PeaceHealth Southwest Medical Center Foundation
PeaceHealth Networks On Demand
PeaceHealth Ambulatory LLC

PeaceHealth Clinically Integrated Network, LLC PeaceHealth Direct Contracting, LLC

Clare Reassurance, Ltd.
ClareSource, LLC (also known as Zoom Manufacturing LLC)

The consolidated financial statements include the accounts of the Corporation. All significant intercompany transactions and balances have been eliminated.

# (2) Summary of Significant Accounting Policies

#### (a) Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.

#### (b) Cash and Cash Equivalents

Cash and cash equivalents consist of petty cash, cash in demand bank accounts, and all highly liquid debt instruments purchased with an original maturity of three months or less other than those amounts included in assets whose use is limited.

The Corporation maintains cash and cash equivalents on deposit at various institutions, which, at times, exceed the insured limits of the Federal Deposit Insurance Corporation. This exposes the Corporation to potential risk of loss in the event the institution becomes insolvent. Changes in cash equivalents held by investment managers are presented as investing activity on the consolidated statements of cash flows.

#### (c) Short-Term Investments

Short-term investments consist primarily of certificates of deposit, U.S. government, and other investment-grade securities. The maturities of these related securities can exceed one year. Management anticipates the securities will be liquidated within one year. Investment income or loss (including realized and unrealized gains and losses and interest and dividends) is included in the deficit of revenues over expenses.

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

(In thousands)

# (d) Inventory of Supplies

Inventory is valued on weighted average cost.

## (e) Other Receivables

Other receivables primarily consist of amounts receivable from the Oregon Hospital Assessment Program and the Washington State Safety Net Assessment Program, amounts receivable from excess insurance carriers, and other miscellaneous amounts due.

## (f) Assets Whose Use is Limited

Certain assets have been set aside by management of the Corporation for future capital improvements, self-insured liabilities, and payment of future debt payments. Amounts required to meet current liabilities of the Corporation have been reclassified as current in the consolidated balance sheets at June 30, 2023 and 2022. These items consist primarily of investments in marketable equity, fixed-income securities and funds held by third party trustee for current debt payments. Investment income or loss (including realized and unrealized gains and losses and interest and dividends) is included in the deficit of revenues over expenses.

The Corporation accounts for its investments on a trade-date basis. Investment sales and purchases initiated prior to the consolidated balance sheet date and settled subsequent to the consolidated balance sheet date result in amounts due from and to brokers. Changes in these assets and liabilities represent noncash investing activities excluded from the consolidated statements of cash flows.

# (g) Liquidity

Cash and cash equivalents, accounts receivable, and short-term investments are the primary liquid resources used by the Corporation to meet expected expenditure needs within the next year. The Corporation has credit facility programs, as described in note 8, available to meet unanticipated liquidity needs. Although intended to satisfy long-term obligations, management estimates that approximately 70% and 71% of assets whose use is limited, as stated at June 30, 2023 and 2022, respectively, could be liquidated and be made available for general operating purposes within the next year if needed.

# (h) Property, Plant, and Equipment

Property, plant, and equipment are stated at cost at the date of acquisition or fair value at the date of donation. Improvements and replacements of plant and equipment are capitalized. Maintenance and repairs are expensed as they are incurred. When property, plant, and equipment are sold or retired, the cost and the related accumulated depreciation are removed from the accounts, and the resulting gain or loss is recorded.

The Corporation assesses potential impairment of its long-lived assets when there is evidence that events or changes in circumstances have made recovery of the asset's carrying value unlikely. An impairment loss is indicated when the sum of expected undiscounted future net cash flows is less than the carrying amount. The loss recognized is the difference between the fair value and the carrying amount. No impairment losses related to property, plant, and equipment were recognized during the years ended June 30, 2023 or 2022.

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

(In thousands)

# (i) Depreciation and Amortization

Depreciation and amortization on property, plant, and equipment are computed using the straight-line method over the following estimated useful lives:

Land improvements 5–25 Years
Buildings and improvements 5–80 Years
Fixed equipment 10–75 Years

Leasehold improvements Shorter of remaining length

of the lease or useful life

Moveable equipment 3–30 Years

# (j) Other Assets

Other assets include intangible assets, primarily trade names, and goodwill. Intangible assets with indefinite lives are evaluated annually for impairment. Impairment reviews are performed of the purchased intangible assets whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. There were no impairment losses recognized during the years ended June 30, 2023 or 2022.

# (k) Other Long-Term Liabilities

Other long-term liabilities consist primarily of the estimated fair value associated with the Corporation's interest rate swaps of \$54,426 and \$73,074 at June 30, 2023 and 2022, respectively; the liability for the PeaceHealth's 457(b) and 457(f) postretirement savings plans of \$90,223 and \$76,594 at June 30, 2023 and 2022, respectively; and the long-term portion of the liability for the self-insurance programs of \$52,386 and \$51,256 at June 30, 2023 and 2022, respectively. The remaining balance of other long-term liabilities includes environmental liabilities, gift annuities, and deferred compensation plan liability.

Accounting for asset retirement and environmental obligations requires legal obligations associated with the retirement of long-lived assets to be recognized at fair value when incurred and capitalized as part of the related long-lived asset. In the absence of quoted market prices, the Corporation estimates the fair value of its asset retirement obligations using present value techniques, in which estimates of future cash flows associated with retirement activities are discounted using a credit-adjusted risk-free rate.

The Corporation has created several pooled income funds. Donors make a contribution and receive annuity payments based on the associated rental income. Upon the annuity termination, the remaining interest is transferred to the Corporation. At June 30, 2023 and 2022, the Corporation has recorded the present value of the annuity payments of \$10,737 and \$10,934, respectively, as part of other long-term liabilities. The discount rate ranged from 6.6% to 7.4% at June 30, 2023 and 6.5% to 7.3% at June 30, 2022.

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

(In thousands)

# (I) Net Assets

Net assets without donor restrictions are those that are not subject to donor-imposed stipulations. Net assets with donor restrictions are those whose use by the Corporation have been limited by donor-imposed restrictions to a specific time period, in perpetuity, and/or purpose.

Net assets with donor restrictions represent resources subject to donor-imposed restrictions. Some donor-imposed restrictions are temporary in nature, such as those that are restricted by the donor for a particular purpose and that will be met by the passage of time or other events specified by the donor. Other donor restrictions are perpetual in nature, whereby the donor has stipulated the funds be maintained in perpetuity. When specific donor restrictions are satisfied, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the consolidated statements of operations and the consolidated statements of changes in net assets as net assets released from restrictions.

## (m) Contributions and Grants

Contributions and grants are recognized as revenue upon receipt of the donor's pledge to contribute. Contributions and grants are considered to be available for unrestricted use unless specifically restricted by the donor. Amounts pledged that are restricted by the donor for specific purposes are reported as net assets with donor restrictions. Unconditional promises to give that are silent as to the due date are presumed to be time restricted by the donor until received and are reported as net assets with donor restrictions.

A donor restriction expires when an unconditional promise with an implied time restriction is collected or when the purpose for the restriction is accomplished. Upon expiration, net assets with donor restrictions are reclassified to net assets without donor restrictions and are reported in the consolidated statements of operations as net assets released from restrictions. Restricted contributions received in the same year in which the restrictions are met are recorded as an increase in restricted support at the time of receipt and as net assets released from restrictions at the time restrictions are met.

#### (n) Interest in Net Assets of Related Foundations

The Corporation recognizes its interest in its unconsolidated related foundations representing certain net assets that will ultimately benefit the Corporation. The Corporation records an asset on the consolidated balance sheets for its beneficial interest in net assets of related foundations. The Corporation recognizes changes in this beneficial interest in the consolidated statements of changes in net assets.

#### (o) Other Operating Revenue

Other operating revenue includes revenue from nonpatient care services, clinical space rental revenue, and other miscellaneous revenue. Such revenue is generally recognized at point of service for these transactions in accordance with Accounting Standards Codification Topic 606, *Revenue from Contracts with Customers*. Other operating revenue also includes contributions both unrestricted in nature and those released from restriction to support operating activities and COVID-19-related grant income.

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

(In thousands)

# (p) Nonrecurring Operating Loss

The Corporation recorded a nonrecurring operating loss in the amount of \$19,122 and \$16,494 in the years ended June 30, 2023 and 2022, respectively. These settlements have been presented as nonrecurring in the operating section of the statement.

## (q) Loss from Operations

Loss from operations excludes certain items that the Corporation deems outside the scope of its primary business, such as investment return, change in valuation of interest rate swaps, and other items.

# (r) Deficit of Revenues over Expenses

Deficit of revenues over expenses includes results from the Corporation's operating and nonoperating investing activities. Investment return includes interest income, dividends, and realized and unrealized investment gains and losses. Changes in net assets without donor restrictions not included in deficit of revenues over expenses include net assets released from restriction for the purchase of property, changes in the Corporation's interest in the net assets of noncontrolled foundations, and certain changes in funded status of the pension plan.

## (s) Federal and State Income Taxes

PeaceHealth and PeaceHealth Networks have received determination letters from the Internal Revenue Service stating that they are exempt from federal and state income tax under Section 501(c)(3) of the Internal Revenue Code except for tax on unrelated business income. It is management's belief that none of its activities have produced material unrelated business income. The Corporation recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that exceeds a 50% probability of being realized. Changes in recognition or measurement are reflected in the period in which the change in estimate occurs.

Certain affiliated entities included in the consolidated financial statements may be subject to taxation. The tax expense and related provision for these entities are not material to the consolidated financial statements.

# (3) Revenue Recognition

#### (a) Patient Service Revenue

Patient service revenue relates to contracts with patients involving third-party payors where the Corporation has an obligation to perform healthcare services. This revenue is recorded at the amount due from patients, third-party payors, and others when the performance obligations are satisfied. The Corporation bases the implicit price concessions on historical collectibility data by payor using a portfolio approach to recognize the deductions netted against revenue when it is recognized.

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

(In thousands)

The Corporation has also entered into payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations. The basis for payment to the Corporation under these agreements includes prospectively determined rates per unit of service and discounts from established charges, as well as risk-sharing arrangements. Most arrangements provide for payment or reimbursement to the Corporation at amounts different than established rates. Explicit price concessions represent the difference between established rates for services and amounts paid or reimbursed by these third-party payors. Risk-sharing arrangements include incentive payments for specific quality outcomes, effective management of costs, and other measures, and in some cases may result in a penalty.

The Corporation provides care to patients who meet certain criteria under its charity care policy without charge or at amounts less than its established rates. Because the Corporation does not pursue collection of amounts determined to qualify as charity care, they are not reported as revenue.

The Corporation maintains records to identify and monitor the level of charity care it provides. These records include the amount of charges forgone for services and supplies under its charity care policy. Estimated costs (based on the proportion of overall costs to charges foregone for charity care) for services and supplies furnished under the charity care policy for the years ended June 30, 2023 and 2022 were approximately \$54,423 and \$47,906, respectively.

## (b) Disaggregation of Revenue

The Corporation earns the majority of its revenues from contracts with customers. Revenues and adjustments not related to contracts with customers are included in other revenue.

Total revenues from contracts with customers by payor are as follows for the years ended June 30:

	2023	2022
Medicare \$	1,407,101	1,299,990
Medicaid	408,566	384,013
Commercial and other	1,464,109	1,403,333
Private pay	17,576	16,008
Patient service revenue	3,297,352	3,103,344
Other revenue	90,729	187,273
Total revenue \$	3,388,081	3,290,617

Note 4 includes discussion of the federal stimulus payments received for COVID-19 included in other revenue.

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

(In thousands)

## (c) Variable Consideration

Reimbursement for inpatient and outpatient services rendered to Medicare recipients has been made principally under a prospective pricing system. Services to Medicaid patients are also reimbursed based on a combination of prospectively determined rates and cost reimbursement methodology. Continuation of these reimbursement programs at the present level, and on the present basis, is dependent upon future policies of federal and state governmental agencies. The Corporation operates five critical access hospitals that are reimbursed based on costs for inpatient and outpatient services rendered to Medicare and Medicaid program beneficiaries. Interim reimbursement to critical access hospitals is based upon tentative rates and retroactive adjustment is made to actual cost during final settlement by either the Medicare fiscal intermediary or the applicable state's Medicaid agency.

Patient service revenue is recognized at the time services are provided to patients. Revenue is recorded in the amount which the Corporation expects to collect, which may include variable components. Variable consideration is included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with variable consideration is subsequently resolved. The Corporation has estimated payments for services rendered to Medicare and Medicaid patients during the year by applying the payment principles of the applicable governmental agencies and believes that an adequate provision has been made in the accompanying consolidated financial statements for final settlement. Estimates of final settlements due to and due from Medicare, Medicaid, and other third-party payors are included in other current liabilities in the accompanying consolidated balance sheets. Differences between the net amounts accrued and subsequent settlements are recorded in operations at the time of settlement. The net amount of adjustments from finalization and adjustment of prior years' cost reports and other third-party settlements resulted in a decrease in patient service revenue of approximately \$10,293 and \$2,335 in 2023 and 2022, respectively.

Laws and regulations governing the Medicare and Medicaid programs are extremely complex and subject to interpretations. As a result, there is at least a reasonable possibility that recorded estimates associated with these programs will change by a material amount in the near term.

#### (d) Concentration of Credit Risk

There is a corresponding significant concentration of credit risk in net accounts receivable balances at June 30:

	2023	2022
Medicare	35 %	36 %
Medicaid	10	8
Commercial and other	47	48
Private pay	8	8
	100 %	100 %

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

(In thousands)

# (4) COVID-19

During the COVID-19 pandemic, federal, state, and local authorities undertook several actions designed to assist healthcare providers in providing care to COVID-19 and other patients and to mitigate the adverse economic impact of the COVID-19 pandemic. Legislative actions taken by the federal government included the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), the Paycheck Protection Program and Health Care Enhancement Act, the Continuing Appropriations Act, 2021 and Other Extensions Act, and the Consolidated Appropriations Act, 2021 (collectively, the COVID Acts).

With the COVID Acts, the federal government authorized funding to be distributed through the Public Health and Social Services Emergency Fund (Provider Relief Fund or PRF). On June 2021, the U.S. Department of Health and Human Services (HHS) established new deadlines for when recipients of PRF grants must use the funding received, generally 12 to 18 months after receipt of the grant funds. HHS will recoup PRF grant funds not utilized by the established deadlines. The Corporation received approximately \$214,263 in total payments from the PRF of which \$1,892 and \$78,451 were recognized as other operating revenue for the years ended June 30, 2023 and 2022, respectively.

The Coronavirus Aid, Relief and Economic Security Act (the CARES Act) expanded the Medicare Accelerated and Advance Payment Program to increase cash flow to providers impacted by the COVID-19 pandemic. The Medicare Accelerated and Advanced Payment Program payments are advances that providers must repay. Providers are required to repay accelerated payments beginning one year after the payment was issued. After such one-year period, Medicare payments owed to providers will be recouped according to the repayment terms. The accelerated payments as of June 30, 2023 and 2022, respectively, were \$0 and \$89,419, which have been accrued on the consolidated balance sheets as a contract liability in the Medicare advance funding current liability.

The COVID Acts also permitted employers to defer payment of the 6.2% employer Social Security tax beginning March 27, 2020 through December 31, 2020, with 50% of the deferred amount due December 31, 2021 and the remaining 50% due December 31, 2022. The Corporation began deferring the employer portion of social security taxes in mid-April 2020. As of June 30, 2023 and 2022, respectively, the Corporation deferred \$0 and \$26,088 in social security taxes, which are included in accrued payroll, payroll taxes and employee benefits in the accompanying consolidated balance sheets.

COVID volumes resulted in high levels of contract labor resulting in a negative impact on operations. The Corporation incurred temporary labor costs for the year ended June 30, 2023, and 2022 respectively of \$153,852 and \$319,906 which were reported in salaries and wages in the accompanying consolidated statements of operations.

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

(In thousands)

## (5) Fair Value of Financial Instruments

Accounting Standards Codification (ASC) Topic 820, *Fair Value Measurement*, requires a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Corporation has the ability to access at the measurement date.
- Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
- Level 3 inputs are unobservable inputs for the asset or liability.

The level in the fair value hierarchy within which a fair value measurement in its entirety falls is based on the lowest-level input that is significant to the fair value measurement in its entirety. Investments valued utilizing net asset value (NAV) as a practical expedient are excluded from the hierarchy.

The fair value of investments, other than those measured using NAV as a practical expedient for fair value, is estimated using quoted market prices multiplied by shares held or other observable inputs when quoted market prices are unavailable.

Registered mutual funds and money market funds are classified in Level 1 of the fair value hierarchy as defined above because their fair values are based on quoted prices for identical securities.

The common/collective trusts have been determined to trade daily at NAV at the trading price and are classified in Level 2 of the fair value hierarchy, as defined above.

The Corporation uses a practical expedient for the estimation of the fair value of investments in funds for which the investment does not have a readily determinable fair value. The practical expedient used by the Corporation is the NAV per share or its equivalent. In some instances, the NAV may not equal the fair value that would be calculated under fair value accounting standards. Investments in hedge funds, real estate funds, and private equity investments are carried at estimated fair value using NAV as a practical expedient as determined by the external investment manager. Valuations provided by fund administrators consider variables, such as the financial performance of underlying investments, recent sales prices of underlying investments, and other pertinent information. In addition, actual market exchanges at year-end provide additional observable market inputs of the exit price. Management reviews the valuations and assumptions provided by fund administrators for reasonableness and believes that the carrying amounts of these financial instruments are reasonable estimates of fair value. The initial valuation is adjusted when changes to inputs and assumptions are corroborated by evidence, such as transactions of similar securities; completed or pending third-party transactions in the underlying security or comparable entities; offerings in the capital markets; and changes in financial results, data, or cash flows. For positions that are not traded in active markets or are subject to notice provisions, valuations are adjusted to reflect such provisions, and such adjustments are generally based on available market evidence.

Notes to Consolidated Financial Statements
June 30, 2023 and 2022
(In thousands)

# (6) Investments

The composition of short-term investments and assets whose use is limited carried at fair value on a recurring basis at June 30, 2023 is set forth in the following table:

		Fair value measurements at reporting date using		
	June 30, 2023	Level 1	Level 2	Level 3
Assets:				
Cash equivalents	\$ 165,470	165,470	_	_
Fixed income:				
Government, municipal, foreign,				
and other	212,652	100,572	112,080	_
Corporate obligations	176,751	_	176,751	_
Mutual funds:				
Fixed income	72,105	72,105	_	_
Domestic equities	526,153	526,153	_	_
International equities	251,966	251,966	_	_
Other	90,693	90,693	_	_
Other long-term equity investments	20,509	20,509		
Total assets at fair value	1,516,299	1,227,468	288,831	_
Investments measured at NAV:				
Hedge funds	191,511	_	_	_
Private equity	379,683	_	_	_
Real estate limited partnerships	101,896			
Total assets	\$ 2,189,389	1,227,468	288,831	
Liabilities:				
Interest rate swaps	\$ 54,426		54,426	
Total liabilities	\$ 54,426		54,426	

Notes to Consolidated Financial Statements
June 30, 2023 and 2022
(In thousands)

The composition of short-term investments and assets whose use is limited carried at fair value on a recurring basis at June 30, 2022 is set forth in the following table:

		Fair value measurements at reporting date using			
	June 30, 2022	Level 1	Level 2	Level 3	
Assets:					
Cash equivalents	\$ 125,032	125,032	_	_	
Fixed income:					
Government, municipal, foreign,					
and other	129,376	65,292	64,084	_	
Mortgage and asset-backed					
securities	63,664	_	63,664	_	
Corporate obligations	218,725	_	218,725	_	
Other short-term investments	7,136	77	7,059	_	
Common/collective trusts	15,350	_	15,350	_	
Hedge funds and other	28,819	_	28,819	_	
Mutual funds:					
Fixed income	71,314	71,314	_	_	
Domestic equities	584,600	584,600	_	_	
International equities	337,953	337,953	_	_	
Other	80,206	80,206	_	_	
Other long-term equity investments	27,706	27,706			
Total assets at fair value	1,689,881	1,292,180	397,701	_	
Investments measured at NAV:					
Hedge funds	248,351	_	_	_	
Private equity	279,165	_	_	_	
Real estate limited partnerships	104,300				
Total assets	\$ 2,321,697	1,292,180	397,701		
Liabilities:					
Interest rate swaps	\$ 73,074		73,074		
Total liabilities	\$ 73,074		73,074		

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

(In thousands)

The Corporation holds investments in private equity and distressed debt limited partnerships where NAV is used as a practical expedient to measure fair value at June 30, 2023 and 2022. These partnerships do not allow for periodic redemptions but rather liquidate upon the termination date as stated in the partnership agreement. Therefore, the private equity investments are considered illiquid investments. At June 30, 2023 and 2022, the Corporation held \$379,683 and \$279,165, respectively, of private equity and distressed debt limited partnerships that had termination dates that ranged from 2023 to 2033. As of June 30, 2023, the Corporation had a capital commitment of \$14,112 to distressed debt and \$128,788 to private equity.

	 2023	2022	commitments
Distressed debt	\$ 3,021	232	14,112
Private equity	 376,662	278,933	128,788
Total	\$ 379,683	279,165	142,900

The following table summarizes investments measured at fair value based on NAV per share as of June 30, 2023 and 2022 and their redemption restrictions:

	Fair value at June 30, 2023	Fair value at June 30, 2022	Lockup terms or redemption restrictions	Redemption frequency	Redemption frequency
Hedge funds	\$ 26,052	38,126	None	Monthly	10 Days
Hedge funds	11,568	10,000	None	Monthly	15 Days
Hedge funds	14,135	22,241	None	Monthly	30 Days
Hedge funds	14,806	17,831	None	Monthly	60 Days
Hedge funds	13,078	13,961	Gate at 20% of total fund net assets	Monthly	60 Days
Hedge funds	10,426	20,414	None	Semimonthly	30 Days
Hedge funds	23,540	26,298	Gate at 50% of total fund net assets	Quarterly	60 Days
Hedge funds	32,667	30,638	None	Quarterly	60 Days
Hedge funds	15,180	19,755	Gate at 10%	Quarterly	65 Days
·			Withdrawal limits across four	·	·
Hedge funds	18,288	20,952	successive withdrawal dates	Quarterly	90 Days
Hedge funds	_	20,696	None	Quarterly	90 Days
Hedge funds	11,771	7,439	None	Quarterly	30 Days
·			First business day of the calendar	·	·
Real estate	69,825	72,188	quarter with 45 days notice	Quarterly	45 Days
Real estate	25,137	29,980	Two-year lockup period	N/A	N/A
Real estate	6,934	2,132	None	Illiquid	Illiquid
	\$293,407_	352,651			

## Other Investments

Health Ventures is a not-for-profit corporation that has entered into joint ventures to provide radiology, oncology, dialysis, and surgery services. PeaceHealth is the sole member of Health Ventures. Health

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

(In thousands)

Ventures is included in the consolidated financial statements but is not part of the obligated group. The majority of these joint ventures are accounted for under the equity method. Health Venture's ownership interest in the joint ventures ranged from approximately 25.2% to 50% at June 30, 2023 and 2022.

During the fiscal year ended June 30, 2022, PeaceHealth invested in Ardon Health, a pharmacy company, and Emerging Health, an infusion services company. PeaceHealth purchased 35% ownership interest in Ardon Health Holdings, which owns 100% of Ardon Health and Emerging Health. Ardon Health is held directly by PeaceHealth and is not part of Health Ventures.

As of June 30, 2023 and 2022, the carrying value of the joint ventures was approximately \$61,513 and \$58,658, respectively, and is recorded in investments in joint ventures and other on the consolidated balance sheets. Equity earnings from the joint ventures of \$17,209 and \$13,022 for the years ended June 30, 2023 and 2022, respectively, are included in other operating revenue. The assets, liabilities, and equity of these joint ventures accounted for under the equity method were \$189,519, \$50,890, and \$138,629, respectively, at June 30, 2023 and \$182,064, \$45,239, and \$136,825, respectively, at June 30, 2022.

At June 30, 2023, Health Ventures had a controlling ownership of 51.16% in Riverbend Ambulatory Surgery Center, which is consolidated within Health Ventures.

# (7) Leases

The Corporation leases office space and clinic facilities under various noncancelable operating leases. The Corporation determines if an arrangement is a lease at inception of the contract. For leases with terms greater than 12 months, the Corporation records the related right-of-use (ROU) asset and lease liability at the present value of the lease payments over the contract term using the Corporation's incremental borrowing rate. Right-of-use assets represent the Corporation's right to use the leased assets over the life of the lease and are derived from the lease liability, adjusted by any lease payments made prior to lease commencement, initial direct costs, and/or lease incentives. Building lease agreements generally require the Corporation to pay maintenance, repairs, and property taxes, which are variable based on actual costs incurred during each applicable period. Such costs are not included in the determination of the ROU asset or lease liability. Variable lease costs also include escalating rent payments that are not fixed at lease commencement but are based on an index that is determined in future periods over the lease term based on changes in the Consumer Price Index or other measures of cost inflation. Most leases include one or more options to renew the lease at the initial term, with renewal terms that generally extend the lease at the then market rate of rental payment. The exercise of lease renewal options is at the Corporation's sole discretion and are only included in the ROU asset and liability if reasonably certain to be exercised at commencement of the lease.

Rent expense for the leases was \$43,052 and \$43,668 for the fiscal years ended June 30, 2023 and 2022, respectively and is included in purchased services on the consolidated statements of operations and changes in net assets without restrictions.

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

(In thousands)

The following table presents the components of the lease assets and lease liabilities related to their classification in the accompanying consolidated balance sheets as of June 30, 2023 and 2022:

	 2023	2022
Operating leases:		
Operating lease right-of-use assets	\$ 95,009	88,918
Short-term lease liabilities	\$ 11,834	10,425
Long-term lease liabilities	 87,781	82,817
	\$ 99,615	93,242
Weighted average lease term – operating leases	8.31 years	9.3 years
Weighted average discount rate – operating leases	3.81 %	3.79 %

Supplemental cash flow and other information related to leases as of and for the year ended June 30 are as follows:

	 2023	2022
Operating cash flows from operating leases	\$ 27,375	26,868
Right-of-use assets obtained in exchange for operating lease obligations	\$ 23,783	28,096

The future minimum lease payments that are required under the above operating leases as of June 30, 2023 were as follows:

2024		\$	19,485
2025			18,712
2026			17,327
2027			15,908
2028			11,676
Thereafter		_	33,250
			116,358
Less: amoun interest	t of lease payments representing	_	(16,743)
	Present value of minimum future		
	lease payments		99,615
Less: current	lease obligation	-	(11,834)
	Long-term lease obligation	\$	87,781

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

(In thousands)

# (8) Long-Term Debt

Long-term debt at June 30 consisted of the following:

	Maturing	ng Coupon or current variable rates			Unpaid p	orincipal	
	through	2023	2022	_ :	2023	2022	
Master trust debt:							
Fixed rate:							
2012 Direct Note Obligation to Bank of America	2022	2.32 %	2.32 %	\$	_	3,367	
2013 Direct Note Obligation to Bank of America	2023	3.23 %	3.23 %	•	1,937	7,642	
Series 2014 Oregon Bonds, Series A	2032	4.125%-5.00%	4.125%-5.00%		51,845	54,750	
Series 2018 Taxable Bonds	2048	4.79 %	4.79 %		355,144	355,144	
Series 2020 Taxable Bonds	2050	1.375%-3.218%	1.375%-3.218%	_	741,305	741,305	
Total fixed rate				\$	1,150,231	1,162,208	
Variable:							
Series 2013 Washington Bonds, Series A,							
variable interest rate (68%*1ml+70 bps),	2034	3.39 %	1.42 %	\$	40,365	41,965	
Series 2018 Oregon Bonds, Series Avariable							
interest rate (prevailing market rates),	2034	2.28 %	0.58 %		45,975	45,975	
Series 2018 Oregon Bonds, Series B variable							
interest rate (prevailing market rates),	2034	2.22 %	0.52 %		100,000	100,000	
Series 2018 Oregon Bonds, Series C							
variable interest rate (80%1ml+ 62 bps),	2047	3.74 %	1.47 %	-	75,000	75,000	
Total variable rate				\$	261,340	262,940	
Unpaid principal, master trust debt				\$	1,411,571	1,425,148	
Premium and other on long-term debt				Ψ_	(3,365)	(3,625)	
Master trust debt, including							
premiums and discounts, net					1,408,206	1,421,523	
premiums and discounts, net					1,400,200	1,421,020	
Lines of credit					243,476	27,450	
Other long-term debt				_	13,051	14,770	
Total long-term debt					1,664,733	1,463,743	
	Maturing	Coupon or curre	ent variable rates		Unpaid p	rincinal	
	through	2023	2022		2023	2022	
Less amounts due within one year				\$_	(8,073)	(14,409)	
Total long-term debt due after one year				\$	1,656,660	1,449,334	
ono jour				Ψ=	.,500,000	.,110,001	

 $<sup>^{\</sup>star}\,\,$  ML as used in the table above is defined as monthly LIBOR.

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

(In thousands)

PeaceHealth Networks and PeaceHealth are the sole members of the PeaceHealth Obligated Group. The assets of the obligated group are available for the satisfaction of debts of PeaceHealth and PeaceHealth Networks under the terms of its master trust indenture.

The Washington 2013(A) Direct Placement Bonds, 2018 Oregon Series A-B Variable Rate Demand Bonds and the 2018 Oregon Series C Direct Placement Bonds have variable interest rates that may bear interest at a daily, weekly, 28 day, monthly, semiannual, or annual rates. The rate determination mode may be changed upon request of PeaceHealth and PeaceHealth Networks. The bonds are subject to optional redemption by PeaceHealth and PeaceHealth Networks, in whole or in part, at 100% of the principal amount plus accrued interest. The Washington 2013(A) bonds can be converted to publicly held variable rate demand bonds if PeaceHealth and PeaceHealth Networks chooses. The continuing covenant agreement for the Washington 2013(A) bonds requires a minimum two-year notice period prior to any anniversary of the date of issue occurring on or after February 27, 2016 to be given from the bank to PeaceHealth if the bank chooses to no longer hold the debt, provided that PeaceHealth is in compliance with financial covenants. Letters of credit supporting the 2018 Oregon Series A-B Bonds expire October 31, 2023 and 2024 and are extendable by the banks upon request from PeaceHealth and PeaceHealth Networks. Subsequent to June 30, 2023, the letter of credit supporting the 2018 Series B bonds was extended to a new expiration date of October 31, 2026. The Washington 2013 A Direct Placement Bonds, the 2018 Oregon Series A-B Variable Rate Demand Bonds and the 2018 Oregon Series C Direct Placement Bonds are matched to fixed payor swaps ranging between 3.60% and 4.10% for approximately their par value, the notional amounts of swaps amortizing proportionately to the bonds.

Scheduled principal payments of long-term debt, excluding the premium on bonds, as due according to their original long-term amortization schedule and other debt according to its original maturity schedule for the next five years and thereafter are as follows:

	_	Long-term debt	Finance leases, line of credit, and other	Total
Year ending June 30:				
2024	\$	6,632	1,983	8,615
2025		4,880	1,717	6,597
2026		343,369	245,079	588,448
2027		5,560	642	6,202
2028		5,850	512	6,362
Thereafter	_	1,045,280	17,565	1,062,845
Total	\$	1,411,571	267,498	1,679,069

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

(In thousands)

	Long-term debt	 Finance leases, line of credit, and other	Total
Less amounts representing interest Less amounts representing line of credit		\$ (10,971) (243,476)	(10,971) —
Present value of net minimum finance lease payments		\$ 13,051	
Total long-term debt			\$ 1,668,098

The PeaceHealth Master Trust Indenture, the loan agreements, and other contractual documents under which bonds were issued include covenants, which, among others, obligate PeaceHealth and PeaceHealth Networks to maintain patient service revenue at levels sufficient to achieve specified debt service coverage ratios, meet certain financial tests before additional debt can be incurred, and meet certain financial tests before there can be any significant disposition of property.

The Corporation increased the revolving line of credit with Bank of America to \$125,000. The line of credit bears interest at BSBY Daily Floating Rate expiring in December 2025. At June 30, 2023, \$115,809 was drawn on the line of credit.

The Corporation increased the revolving line of credit with U.S. Bank to \$175,000. The line of credit bears interest at SOFR expiring in December 2025. At June 30, 2023, \$127,667 was drawn on the line of credit.

Cash paid for interest totaled approximately \$50,759 and \$41,603 for the years ended June 30, 2023 and 2022, respectively.

Deferred financing costs are amortized over the lives of the related debt issuances using the effective-interest method.

#### (9) Accounting for Derivative Instruments and Hedging Activities

In accordance with the policy adopted by the board of directors, the Corporation may use interest rate swap contracts to manage its net exposure to interest rate changes in attempting to reduce its overall cost of borrowing over time. Interest rate swap contracts generally involve the exchange of fixed and floating interest rate payments without the exchange of underlying principal (the swap of fixed or floating rates are on a notional amount). The Corporation accounts for its interest rate hedging transactions in accordance with Financial Accounting Standards Board (FASB) ASC Topic 815, *Derivatives and Hedging*. That standard requires that every derivative instrument be recorded on the balance sheet as either an asset or a liability measured at its estimated fair value. The interest rate swaps do not meet the criteria for hedge accounting and all changes in the valuation of the interest rate swaps are included in net change in interest rate swaps on the consolidated statements of operations and changes in net assets without donor restrictions.

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

(In thousands)

The Corporation has interest rate swap contracts outstanding as of June 30, 2023 and 2022, respectively, with a total current notional amount of approximately \$334,075 and \$335,650. The Corporation uses the fixed payor swaps to convert a portion of the outstanding variable rate bonds to fixed rates ranging from 3.50% to 4.15%. The fixed payor interest rate swaps are associated with the variable rate bonds but have not been integrated to any of the underlying debt for the purpose of hedge accounting.

Change in valuation of interest rate swaps consists of the noncash change in the liability primarily due to changes in market bond yields, as well as the cash payments and receipts associated with the swaps, and the amortization of the accumulated hedge effectiveness included in net assets. The noncash change in the fair value of the interest rate swaps was a decrease of \$18,648 and \$62,678 in the liability for the years ended June 30, 2023 and 2022, respectively. Net cash settlement cost for the interest rate swaps was \$4,515 and \$12,778, for the years ended June 30, 2023 and 2022, respectively. The amortization of the accumulated hedge effectiveness included in net assets was \$79 for both years ended June 30, 2023 and 2022.

Derivative instruments are recorded at fair value taking into consideration the Corporation's nonperformance risk and the respective counterparty's nonperformance risk in the fair value measurements. The impact of taking into account the nonperformance risk on the estimated fair value of the interest rate swaps was a benefit of approximately \$3,244 and \$5,941, as of June 30, 2023 and 2022, respectively. The inputs used to determine the impact of the counterparty nonperformance risk are Level 2 inputs; as such, derivative liabilities have been recorded as Level 2 in the Corporation's disclosure of fair value instruments (note 6).

The Corporation currently has five swap counterparties, which minimize counterparty risk and collateral posting requirements. These swap agreements contain various credit thresholds that, if breached by the Corporation, would constitute an additional termination event whereby the swap counterparties could terminate the swap by either making a payment to, or receiving a payment from the Corporation, depending upon the termination value of the swaps as of the date of termination. The Corporation retains the right to terminate the swaps at any point, which would also require either making or receiving a payment depending on the termination value of the swap as of the termination date.

The following is a summary of the derivative instruments in place as of June 30, 2023 and 2022:

Maturity date		Current notional amounts at June 30, 2023	Current notional amounts at June 30, 2022	Counterparty		Credit value adjustment at June 30, 2023	Liability fair value at June 30, 2023	Credit value adjustment at June 30, 2022	Liability fair value at June 30, 2022
August 31, 2034	\$	45,000	45,000	Union Bank, N.A.	\$	59	(4,815)	255	(7,450)
May 24, 2047		75,000	75,000	Barclay Bank PLC		1,294	(16,543)	2,483	(21,929)
May 22, 2047		75,000	75,000	Mizuho Capital Markets LLC	;	1,722	(19,237)	2,483	(21,929)
August 01, 2034		50,000	50,000	U.S. Bank N.A.		70	(5,780)	300	(8,759)
August 01, 2034		50,000	50,000	U.S. Bank N.A. Morgan Stanley Capital		70	(5,772)	300	(8,750)
September 01, 2034	-	39,075	40,650	Services LLC		29	(2,279)	120	(4,257)
	\$	334,075	335,650		\$	3,244	(54,426)	5,941	(73,074)

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

(In thousands)

# (10) Benefit Plans

# (a) Defined-Benefit Pension Plan

The Corporation sponsored a noncontributory, defined-benefit pension plan, the Southwest Washington Health System Retirement Plan, now known as PeaceHealth SWHS Frozen DB Pension Plan (the Plan), covering all employees at PeaceHealth Southwest Medical Center who meet requirements as specified in the Plan. The assets of the Plan were available to pay the benefits of all eligible employees of the Plan. The Plan had two benefit structures that included a cash balance and a final average pay structure. Effective December 31, 2010, the Plan was frozen. No new participants were admitted to the Plan after this date. This event did not terminate the Plan. Benefits earned before the plan was frozen continued to be paid prior to transferring the funds into annuities to prepare for termination.

A plan amendment was made effective December 31, 2016 to spin off a group of participants into PeaceHealth SWHS Frozen DB Pension (Plan II). As of that date, the Plan was renamed PeaceHealth SWHS Frozen DB Pension (Plan I). The PeaceHealth SWHS Plan I and Plan II were collectively referred as "the Plans." Plan provisions were identical between the Plans. The plan split was effective January 1, 2017.

A plan amendment was adopted effective December 31, 2018 to terminate the PeaceHealth SWHS Frozen DB Pension Plan II subject to approval by the Internal Revenue Service and the Pension Benefit Guaranty Corporation (PBGC). A favorable determination letter from the IRS was received for the plan termination. The final settlement of remaining assets and expenses occurred during fiscal year 2022.

A plan amendment was adopted effective December 31, 2020 to terminate the PeaceHealth SWHS Frozen DB Pension Plan I subject to approval by the Internal Revenue Service and the Pension Benefit Guaranty Corporation (PBGC). A favorable determination letter from the IRS was received for the plan termination. During the year ended June 30, 2022, the Plan purchased annuities and paid benefits to satisfy the benefit obligation. The termination resulted in the realization of \$78,958 in losses for the year ended June 30, 2022, which are recognized in other income (expense) on the consolidated statements of operations and changes in net assets without donor restrictions. The final settlement of remaining assets and expenses occurred during fiscal year 2023.

Notes to Consolidated Financial Statements
June 30, 2023 and 2022
(In thousands)

The following table sets forth disclosures related to the Plans in accordance with FASB ASC Paragraph 715-20-65, *Employers' Accounting for Defined Benefit Pension and Other Postretirement Plans*, as of June 30, 2023 and 2022, measured as of January 1, 2023 and 2022, respectively:

	Year ended June 30		
		2023	2022
Change in project benefit obligation:			
Project benefit obligation (PBO) at beginning of period	\$	_	192,701
Service cost		(119)	263
Interest cost		_	1,113
Settlement loss		_	11,069
Actuarial loss on PBO		_	(355)
Benefits and administrative expenses paid		119	(204,791)
Projected benefit obligation at June 30	\$	<u> </u>	
Change in fair value of plan assets:			
Fair value of assets at beginning of period	\$	427	189,231
Actual return on plan assets		_	2,626
Employer contribution		_	13,361
Benefits paid		(119)	(203,988)
Administrative expenses			(803)
Reversion to the plan sponsor		(308)	
Fair value of assets at June 30	\$	<u> </u>	427
Reconciliation of funded status:			
Funded status	\$	<u> </u>	427
Net amount recognized	\$		427
Amounts recognized in the consolidated balance sheets consist of:			
Accrued pension liability	\$	_	_
Accumulated change in net assets		_	26,659

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

(In thousands)

Net periodic benefit cost for the years ended June 30, 2022, included the following components and is included in changes in net assets without donor restrictions:

Service cost	\$ 263
Interest cost	1,113
Expected return on plan assets	(1,502)
Amortization of loss	 79,112
Net periodic pension cost	\$ 78,986

# (b) Assumptions

The Corporation used the following actuarial assumptions to determine its net periodic benefit cost for the years ended June 30, 2022:

Discount rate 2.06 %

This discount rate is based on a proprietary yield curve tool used by the Plans' actuary, which uses a composite of high-yield, investment-grade corporate bonds, and the projected payouts from the Plans to develop an equivalent yield rate to use in determining plan liabilities. For Plan I, the discount rate determined for the valuation at June 30, 2022, was reduced by 50 basis points as an approximation of the rates underlying the annuities to be purchased to settle the benefits for the Plan termination.

## (c) Pension Plan Assets

The asset allocation of the Corporation's pension plan at June 30, 2022 is as follows:

Cash equivalents	\$ 154
Debt securities	_
Others	 273
Total	\$ 427

Pension plan assets use a target allocation of investments to invest 100% of assets in debt securities and cash and cash equivalents.

In accordance with FASB ASC Topic 820, financial assets and financial liabilities measured at fair value are grouped in three levels based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to estimate fair value. These levels and the adoption of FASB ASC Topic 820 are further discussed in note 5.

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

(In thousands)

The following is a description of the valuation methodologies used for plan assets measured at fair value:

- The fair value of cash equivalents is estimated using quoted market prices.
- Private equity fund: Valued at the NAV as a practical expedient as supported by audited financial statements.

The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

The following table sets forth by level, within the fair value hierarchy, the Plans' assets at fair value as of June 30, 2022:

		Total fair			
Assets		value	Level 1	Level 2	Level 3
Cash equivalents	\$_	154_	154		
Total plan assets at fair value		154	154	<u> </u>	
Investments at NAV	_	273			
Total plan assets	\$_	427			

At June 30, 2022, the Plan held \$273 in a private equity investment that is not actively marketed on an open exchange. This investment consists of shares or units in an investment fund as opposed to direct interests in the fund's underlying holdings, which may be marketable. Due to the nature of this fund, the NAV is used as a practical expedient to measure fair value at June 30, 2022. This private equity partnership does not allow for periodic redemptions but rather liquidates upon the termination date as stated in the partnership agreement. Therefore, the private equity investment is considered an illiquid investment. After settlement of the remaining assets and expenses during the year ended June 30, 2023, the private equity investment reverted to the Corporation.

# (11) Defined-Contribution Retirement Plans

PeaceHealth sponsors two defined-contribution retirement plans, the Southwest Washington Health System Retirement Plan and the PeaceHealth Plan. These plans cover substantially all employees of PeaceHealth meeting certain age and length of service requirements. Total defined-contribution retirement plan costs charged to operations were approximately \$97,825 and \$91,196 for the years ended June 30, 2023 and 2022, respectively, which are included in payroll taxes and benefits in the accompanying consolidated statements of operations and changes in net assets without donor restrictions.

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

(In thousands)

## PeaceHealth Deferred Compensation Plans

The estimated fair value associated with the plan assets of PeaceHealth's 457(b) and 457(f) postretirement savings plans, in the amount of approximately \$90,223 and \$76,594 at June 30, 2023 and 2022, respectively, is included in assets whose use is limited, cash equivalents and investments, with a corresponding amount included in other long-term liabilities. Contributions associated with these funds in 2023 and 2022 were \$12,717 and \$11,060, respectively, and are included in payroll taxes and benefits in the accompanying consolidated statements of operations and changes in net assets without donor restrictions.

# (12) Net Assets with Donor Restrictions

Net assets with donor restrictions are available for the following purposes at June 30:

	 2023	2022
Purchase of property, plant, and equipment	\$ 91,562	72,938
Hospice and indigent care	15,980	18,445
Patient care	10,812	12,676
Children's Services	3,755	10,918
Training and education	3,410	2,341
Other	 58,812	57,635
	\$ 184,331	174,953

Approximately \$9,828 and \$4,254 was released from restriction for capital expenditures made during 2023 and 2022, respectively.

#### Charitable Gift Annuities

PeaceHealth has been granted a license by the state of Washington, Office of Insurance Commissioner, to issue Charitable Gift Annuities in support of its charitable activities. The Corporation has delegated all its charitable fundraising activities to several fundraising foundations whose net assets held for the beneficial interest of PeaceHealth are shown on the consolidated balance sheets of the Corporation. The liability for annuity contracts issued under the PeaceHealth license and the separately maintained reserve accounts are recorded on the books of PeaceHealth. As of June 30, 2023 and 2022, the following liabilities for annuity contracts issued under the PeaceHealth license and reserve account investments were recorded:

	 2023	2022	
State of Washington gift annuity liabilities (other long-term			
liabilities)	\$ 1,493	1,538	
Gift annuity reserve accounts (other assets whose use is			
limited, cash, and investments)	1,870	2,142	

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

(In thousands)

# (13) Commitments and Contingent Liabilities

# (a) Litigation

Various laws and regulations of federal, state, and local governments govern the healthcare industry. These laws and regulations are subject to ongoing government review and interpretation, as well as regulatory actions unknown or unasserted at this time. The Corporation is also involved in litigation and regulatory investigations arising in the normal course of business. After consultation with legal counsel, management estimates that these matters will be resolved without material adverse effect on the Corporation's future financial position or results of operations.

# (b) Collective Bargaining Agreements

Approximately 55% and 54% of the Corporation's employees are covered under collective bargaining agreements, including nurses, professional employees, and service employees as of June 30, 2023 and 2022, respectively. The Corporation is currently negotiating certain expired and expiring collective bargaining agreements. Approximately 44% of the Corporation's various collective bargaining agreements expire before June 30, 2024. The remaining agreements expire between September 2024 and April 2027.

# (14) Insurance Coverages

In connection with the self-insurance program, the Corporation has accrued estimates for asserted and incurred but not reported claims, including both the expected liability under each claim and the cost to administer the claim. Self-insured professional and general liability retention was \$7,000 per occurrence and \$40,000 in aggregate in both 2023 and 2022. Individual general and professional liability claims in excess of the above self-insured retention levels are insured through claims-made excess insurance policy.

The Corporation also self-insures all or a portion of liabilities for medical and dental benefit plans, unemployment, and workers' compensation claims. Funding levels and liabilities are determined based on actuarial studies.

Based on actuarial studies, the Corporation has recorded an undiscounted liability for all of the self-insurance programs of approximately \$72,369 and \$77,174 at June 30, 2023 and 2022, respectively. The liabilities are classified within other current liabilities and other long-term liabilities based on the historical amounts paid within one year. Total current amounts included in other current liabilities were approximately \$19,983 and \$25,303 at June 30, 2023 and 2022, respectively. Management has recorded amounts receivable from excess insurance carriers totaling approximately \$5,273 and \$2,624 as of June 30, 2023 and 2022, respectively, which is included in other receivables in the accompanying consolidated balance sheets.

The Corporation is a minority investor in American Excess Insurance Exchange (AEIX). AEIX is a risk retention group owned by a group of healthcare providers and provides them with excess professional liability insurance coverage. The Corporation accounts for its interest in AEIX on the equity method of accounting less mandatory withdrawal penalties and an estimated discount to present value. As of June 30, 2023 and 2022, the carrying value of AEIX was approximately \$1,641 and \$2,746, respectively, and is recorded in investments in joint ventures and other on the consolidated balance sheets. Investment income

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

(In thousands)

from AEIX is recorded as an adjustment to supplies and other operating expenses in the accompanying consolidated statements of operations and change in net assets without donor restrictions.

# (15) Functional Expenses

General and administrative services include costs that benefit the entire organization and are not related to delivery of patient care. Costs that are related to patient care departments are directly assigned to the respective patient care activities. Benefits and other shared costs are allocated based on relative direct costs. Operating expenses related to providing these services classified by their natural classification on the consolidated statements of operations and changes in unrestricted net assets are presented by their functional classifications as follows for the year ended June 30:

		2023			
	_	Patient care	General and administrative	Total expenses	
	_	Care	aummsuative	expenses	
Salaries and wages	\$	1,581,363	260,048	1,841,411	
Payroll taxes and benefits		281,085	72,471	353,556	
Supplies		574,113	5,972	580,085	
Purchased services		364,758	110,733	475,491	
Other		180,088	36,126	216,214	
Depreciation and amortization		62,502	76,474	138,976	
Interest and amortization of deferred financing					
costs	_	260	51,571	51,831	
Total	\$_	3,044,169	613,395	3,657,564	

		2022			
		Patient	General and	Total	
	_	care	administrative	expenses	
Salaries and wages	\$	1,769,529	106,972	1,876,501	
Payroll taxes and benefits		164,277	143,821	308,098	
Supplies		515,324	6,470	521,794	
Purchased services		377,179	76,281	453,460	
Other		211,211	6,048	217,259	
Depreciation and amortization		114,089	34,880	148,969	
Interest and amortization of deferred financing					
costs		694	41,452	42,146	
Total	\$_	3,152,303	415,924	3,568,227	

Notes to Consolidated Financial Statements
June 30, 2023 and 2022
(In thousands)

# (16) Subsequent Events

In connection with the preparation of the consolidated financial statements in accordance with FASB ASC Topic 855, *Subsequent Events*, the Corporation has evaluated subsequent events through October 10, 2023 which is the date the consolidated financial statements were issued.